FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387061679> ?p ?o ?g. }

• W4387061679 abstract "The incidence and risk factors for persisting pharmacotherapy following surgical treatment of benign prostatic obstruction (BPO) remain unclear.To evaluate the evidence on persisting pharmacotherapy of lower urinary tract symptoms (LUTS) following surgical treatment of BPO.A systematic review of the literature was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses checklist (PROSPERO ID CRD42022310598). PubMed and EMBASE databases were searched in February 2022, with an updated search in October 2022. Studies evaluating pharmacotherapy in men aged >18 yr following surgical treatment of BPO were included.Overall, ten nonrandomized studies and one post hoc analysis of two randomized controlled trials were included. The incidence of persisting medical treatment or medical retreatment varied strongly between time points and investigated surgical techniques. Among the investigated techniques, most data were available for transurethral resection of the prostate (TURP). Persistence of pharmacotherapy after TURP at 6 mo ranged from 8.7% to 57% for the use of alpha-blockers. The use of 5-alpha reductase inhibitors after TURP ranged from 5.5% at 6 mo to 19% at 6-24 mo, whereas the use of antimuscarinics ranged from 3.4% to 28.1% at 6 mo. Data on initiation of pharmacotherapy after TURP also differed between study and type of medication. At 12 yr, the use of alpha-blockers after TURP ranged from 12% to 38%. The risk factors associated with medication after BPO surgery were age, history of diabetes mellitus, history of cerebrovascular accident, preoperative medication use, as well as surgical techniques other than laser enucleation of the prostate.Pharmacotherapy for LUTS is common after BPO surgery. The outcomes following different surgical techniques are heterogeneous, with limited data from randomized controlled trials. Future studies on surgical treatment of BPO should include the use of LUTS-related pharmacotherapy after BPO surgery as a secondary endpoint.In the present systematic review, we investigated the risk of ongoing or novel therapy with drugs following surgery for benign prostate enlargement. We found that a non-negligible proportion of men will need to take drug therapy after surgery. Certain risk factors can be identified, which are associated with a higher risk of drug therapy after surgery." @default.
• W4387061679 created "2023-09-27" @default.
• W4387061679 creator A5012539089 @default.
• W4387061679 creator A5023386699 @default.
• W4387061679 creator A5025348800 @default.
• W4387061679 creator A5043068037 @default.
• W4387061679 creator A5049013103 @default.
• W4387061679 creator A5057978449 @default.
• W4387061679 creator A5068751414 @default.
• W4387061679 creator A5088364554 @default.
• W4387061679 creator A5090885197 @default.
• W4387061679 date "2023-09-01" @default.
• W4387061679 modified "2023-09-29" @default.
• W4387061679 title "Medical Treatment Incidence and Persistence After Surgical Relief of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: A Critical Analysis of the Literature" @default.
• W4387061679 cites W1573720709 @default.
• W4387061679 cites W2002443221 @default.
• W4387061679 cites W2002978234 @default.
• W4387061679 cites W2005179743 @default.
• W4387061679 cites W2013909710 @default.
• W4387061679 cites W2018274836 @default.
• W4387061679 cites W2020986094 @default.
• W4387061679 cites W2024982419 @default.
• W4387061679 cites W2025164982 @default.
• W4387061679 cites W2065439011 @default.
• W4387061679 cites W2105715225 @default.
• W4387061679 cites W2137254108 @default.
• W4387061679 cites W2156546850 @default.
• W4387061679 cites W2163974078 @default.
• W4387061679 cites W2168499550 @default.
• W4387061679 cites W2168942726 @default.
• W4387061679 cites W2205128938 @default.
• W4387061679 cites W2417590446 @default.
• W4387061679 cites W2484519907 @default.
• W4387061679 cites W2526901463 @default.
• W4387061679 cites W2551370105 @default.
• W4387061679 cites W2595597718 @default.
• W4387061679 cites W2600604755 @default.
• W4387061679 cites W2601542979 @default.
• W4387061679 cites W2610437787 @default.
• W4387061679 cites W2796257036 @default.
• W4387061679 cites W2913863236 @default.
• W4387061679 cites W2916579722 @default.
• W4387061679 cites W2945956893 @default.
• W4387061679 cites W2974001892 @default.
• W4387061679 cites W3011805401 @default.
• W4387061679 cites W3096177259 @default.
• W4387061679 cites W3103800201 @default.
• W4387061679 cites W3125458998 @default.
• W4387061679 cites W3133335748 @default.
• W4387061679 cites W3156613216 @default.
• W4387061679 cites W3195447773 @default.
• W4387061679 cites W4308294761 @default.
• W4387061679 doi "https://doi.org/10.1016/j.euf.2023.08.013" @default.
• W4387061679 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37758614" @default.
• W4387061679 hasPublicationYear "2023" @default.
• W4387061679 type Work @default.
• W4387061679 citedByCount "0" @default.
• W4387061679 crossrefType "journal-article" @default.
• W4387061679 hasAuthorship W4387061679A5012539089 @default.
• W4387061679 hasAuthorship W4387061679A5023386699 @default.
• W4387061679 hasAuthorship W4387061679A5025348800 @default.
• W4387061679 hasAuthorship W4387061679A5043068037 @default.
• W4387061679 hasAuthorship W4387061679A5049013103 @default.
• W4387061679 hasAuthorship W4387061679A5057978449 @default.
• W4387061679 hasAuthorship W4387061679A5068751414 @default.
• W4387061679 hasAuthorship W4387061679A5088364554 @default.
• W4387061679 hasAuthorship W4387061679A5090885197 @default.
• W4387061679 hasConcept C120665830 @default.
• W4387061679 hasConcept C121332964 @default.
• W4387061679 hasConcept C121608353 @default.
• W4387061679 hasConcept C126322002 @default.
• W4387061679 hasConcept C126894567 @default.
• W4387061679 hasConcept C141071460 @default.
• W4387061679 hasConcept C168563851 @default.
• W4387061679 hasConcept C2776235491 @default.
• W4387061679 hasConcept C2777562237 @default.
• W4387061679 hasConcept C2777590997 @default.
• W4387061679 hasConcept C2779478474 @default.
• W4387061679 hasConcept C2780542891 @default.
• W4387061679 hasConcept C2780768273 @default.
• W4387061679 hasConcept C500440147 @default.
• W4387061679 hasConcept C61511704 @default.
• W4387061679 hasConcept C71924100 @default.
• W4387061679 hasConcept C77411442 @default.
• W4387061679 hasConcept C84393581 @default.
• W4387061679 hasConceptScore W4387061679C120665830 @default.
• W4387061679 hasConceptScore W4387061679C121332964 @default.
• W4387061679 hasConceptScore W4387061679C121608353 @default.
• W4387061679 hasConceptScore W4387061679C126322002 @default.
• W4387061679 hasConceptScore W4387061679C126894567 @default.
• W4387061679 hasConceptScore W4387061679C141071460 @default.
• W4387061679 hasConceptScore W4387061679C168563851 @default.
• W4387061679 hasConceptScore W4387061679C2776235491 @default.
• W4387061679 hasConceptScore W4387061679C2777562237 @default.
• W4387061679 hasConceptScore W4387061679C2777590997 @default.
• W4387061679 hasConceptScore W4387061679C2779478474 @default.
• W4387061679 hasConceptScore W4387061679C2780542891 @default.
• W4387061679 hasConceptScore W4387061679C2780768273 @default.
• W4387061679 hasConceptScore W4387061679C500440147 @default.
• W4387061679 hasConceptScore W4387061679C61511704 @default.

• next